Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11980622 Oxcarbazepine extended release dosage form

Patent 11980622 was granted and assigned to Apotex on May, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Sandeep Patel0

Navin Vaya0

Krishna Hari Bhandari0

Arunprasath Kaliaperumal0

Bernard Charles Sherman0

Date of Patent

May 14, 2024

0

Patent Application Number

176958810

Date Filed

March 16, 2022

0

Patent Citations

US Patent 9351975 Modified release preparations containing oxcarbazepine and derivatives thereof

0

US Patent 9370525 Modified release preparations containing oxcarbazepine and derivatives thereof

0

US Patent 10220042 Modified release preparations containing oxcarbazepine and derivatives thereof

0

US Patent 9855278 Modified release preparations containing oxcarbazepine and derivatives thereof

0

US Patent 7722898 Modified-release preparations containing oxcarbazepine and derivatives thereof

0

US Patent 7910131 Method of treating seizures using modified release formulations of oxcarbazepine

0

US Patent 8617600 Modified release preparations containing oxcarbazepine and derivatives thereof

0

US Patent 8821930 Modified release preparations containing oxcarbazepine and derivatives thereof

0

...

Patent Primary Examiner

0

Patent abstract

The present invention relates to extended release pharmaceutical dosage forms of oxcarbazepine.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11980622 Oxcarbazepine extended release dosage form

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.